In Vivo Chemistry of Iofetamine HCl Iodine-123 (IMP)
Overview
Authors
Affiliations
Application of chemical methods for characterizing the in vivo behavior of iofetamine HCI 123I (IMP) has shed light on the metabolism of iofetamine in animals and humans. A successful technique consists of ethyl acetate extraction of the metabolites from tissue samples acidified with perchloric acid, separation of the mixture by high performance liquid chromatography, and quantitation of the radioactive components with a sensitive scintillation detector. Metabolism of iofetamine HCI 123I proceeds sequentially from the N-isopropyl group on the amphetamine side chain. The first step, dealkylation to the primary amine p-iodoamphetamine (PIA), occurs readily in the brain, lungs, and liver; activity in the brain and lungs consists of only IMP and PIA even 24 hr after administration. The rate-limiting step appears to be deamination to give the transitory intermediate p-iodophenylacetone, which is rapidly degraded to p-iodobenzoic acid and conjugated with glycine in the liver to give the end product of metabolism, p-iodohippuric acid, which is excreted through the kidneys in the urine.
Tanaka E, Mishima M, Kawakami K, Sakai N, Sugiura N, Taniguchi T Ann Nucl Med. 1995; 9(4):209-13.
PMID: 8770288 DOI: 10.1007/BF03168403.
Prolonged lung retention of 123I-IMP in pulmonary disease.
Ikeda H, Mariko M, Komatsu M, Yasui S, Takahashi K Eur J Nucl Med. 1989; 15(10):646-8.
PMID: 2806325 DOI: 10.1007/BF00251677.
The influence of age on N-isopropyl-p-[123I]iodoamphetamine accumulation in the human heart.
Nakajo M, Nakabeppu Y, Iwashita S, Shinohara S Ann Nucl Med. 1990; 4(2):49-54.
PMID: 2223378 DOI: 10.1007/BF03164595.
Nakajo M, Uchiyama N, Shimada J, Shinohara S, Iriki A, Hirotsu Y Ann Nucl Med. 1990; 4(1):1-13.
PMID: 2169829 DOI: 10.1007/BF03165653.
Prolonged lung retention of 123I-IMP in pulmonary fibrosis.
Ikeda H, Itasaka M, Takahashi K, Komatani A Ann Nucl Med. 1992; 6(3):147-51.
PMID: 1389889 DOI: 10.1007/BF03178306.